Introduction
============

While thyroid cancer is the most common endocrine tumor in adults, it is much less frequent in children and adolescents, accounting for 1.8% of all differentiated thyroid cancer (DTC) cases ([@r1], [@r2]). DTC is generally more advanced at the time of diagnosis in children and adolescents than in adults, with neck lymph node metastasis and distant metastasis (mostly in lungs) occurring in 39%-90% and 6%-41% of patients, respectively ([@r3]-[@r6]). Despite advanced stage at diagnosis and high recurrence rate (11%-45%), the prognosis of pediatric thyroid cancer is more favorable than in adults, with only sporadic cases with fatal outcomes (less than 5%) ([@r7]-[@r10]). As survival rates suggest, thyroid cancer in children and adolescents is genetically different from the adult type, with important clinical, molecular and pathologic divergences, which could prove to be a contributing factor in treatment efficacy ([@r9]). Current standard of care for these patients is surgery (total thyroidectomy) ([@r11]). Application rate of postoperative treatment with radioactive iodine (I-131) varies among centers, but is generally becoming more common in the treatment of pediatric patients ([@r12]). Studies regarding I-131 therapy in children are limited and mostly of low-level evidence, especially in the adjuvant setting ([@r13]). Furthermore, there are no established standardized activities of I-131 for the pediatric population, and these are usually determined based on the individual physician's decision, especially in patients with disseminated disease ([@r10]). Children and adolescents with thyroid cancer are shown to have better progression-free survival (PFS) after I-131 therapy than adult patients, thus it is necessary to assess the potential risk/benefit ratio prior to the application of therapy ([@r5], [@r8]). In the frame of larger proportion of patients with pediatric DTC that receive high activities of I-131 and long overall survival (OS), issues have arisen regarding long-term adverse effects, with particular accent on the development of secondary malignancies. Here we present clinicopathologic data on 45 pediatric patients treated with I-131 for thyroid cancer collected over a 50-year period.

Patients and Methods
====================

The study was conducted in a tertiary high-volume thyroid center, based on data on all pediatric patients with DTC that were evaluated between 1965 and 2015. Inclusion criteria were as follows: ≤18 years of age at diagnosis; and diagnosis of DTC confirmed by histopathologic analysis (total thyroidectomy or lobectomy). There were no additional exclusion criteria, and a total of 45 patients were included in the study. The study was conducted in compliance with ethical standards set by the institutional Ethics Committee and the Helsinki Declaration from 1975, as revised in 1983. Decisions with respect to postoperative I-131 ablation were based on histopathologic tumor characteristics, postoperative thyroglobulin (Tg) level, postoperative anti-Tg antibody (TgAb) level, preablative whole body scintigraphy (WBS), and/or neck ultrasound. Neck ultrasound was performed in all patients after the introduction of the method in 1978, and preablative WBS was selectively performed to estimate the mass of the possible thyroid remnant after surgery. Postoperative WBS was done in all patients that received I-131 therapy. Multiple I-131 therapies were administered in cases of ablation failure, defined as the presence of remnant thyroid tissue (visible accumulation of I-131) in the thyroid bed and cervical region on WBS (Tg level, TgAb level, and neck ultrasound were used as additional diagnostic criteria). Patients were regularly followed-up for disease recurrence and dissemination at 6- to 12-month intervals, until the study cut-off date on December 31, 2016.

All procedures performed in studies involving human participants were in accordance with ethical standards set by the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statistical analysis
--------------------

The normality of distribution of numerical variables was tested using the Shapiro-Wilk test. Numerical variables were presented as median and interquartile range (IQR), and categorical variables were presented as number and percentage. Numerical variables between groups were compared using the Mann Whitney U test and categorical variables were compared between groups using the χ^2^-test. Spearman rank correlation was used to test correlation between numerical variables. Poisson regression was used to test the trend of increase in the number of cases over time. Survival analyses were performed using the methods of Kaplan and Meier and the Cox-Mantel log-rank test ([@r14]). Cut-off point for numerical variables was determined using ROC curve analysis. Data were screened using custom made MS Excel workbook ([@r15]) and re-analyzed using MedCalc Statistical Software version 16.2.0 (MedCalc Software bvba, Ostend, Belgium). The values of p\<0.05 were considered significant. Optimal cut-off points for transforming numerical variables into dichotomous variables for the purpose of survival analysis were determined using ROC curve analysis with PFS status as a classification variable. Age \>15 years and tumor size \>15 mm showed best survival discriminatory properties.

Results
=======

Patient characteristics
-----------------------

A total of 45 pediatric patients with DTC were evaluated, representing 1.5% of all patients in DTC database. Median age at diagnosis was 15 years, IQR 13-16. There were 40 (89%) female and five (11%) male patients, yielding a female to male ratio of 8:1. Patient characteristics are shown in [Tables 1-3](#t1){ref-type="table"}[](#t2){ref-type="table"}[](#t3){ref-type="table"}. The number of patients diagnosed with DTC was stable until the last decade, when a substantial increase in the number of newly diagnosed cases was observed. Overall, there was a significant positive trend of increase in the number of newly diagnosed patients over time (p=0.011), as shown in [Figure 1](#f1){ref-type="fig"}. Patients were further divided into tertiles of the study period to analyze whether outcomes differed in patients treated in different time periods. We observed no significant difference in outcomes between these patient groups (p=0.432), as shown in [Figure 2](#f2){ref-type="fig"}. While the majority of patients received I-131 (91%), the applied activity and number of applications varied, reflecting tumor specific features that guided therapeutic approach. Median total I-131 activity was 3700 MBq (100 mCi) (IQR 65-209), and median number of applications was 1 (IQR 1-2). Median postoperative Tg was 19.4 ng/mL (IQR 13.6-68).

###### Characteristics of pediatric patients with differentiated thyroid cancer at the time of diagnosis (N=45)

  ------------------------------------------------------
  Category                               Number (%)
  -------------------------------------- ---------------
  Histologic diagnosis^a^:\              39/43 (91)\
    Papillary thyroid cancer\            4/43 (9)
    Follicular thyroid cancer            

  Capsule infiltration^b^:\              7/23 (30.4)\
    Present\                             16/23 (69.6)
    Absent                               

  Lobe involvement^c^:\                  19/28 (67.9)\
    Unilobular tumor\                    9/28 (32.1)
    Both lobes involved                  

  Focal tumor distribution^d^:\          19/29 (65.5)\
    Unifocal disease\                    10/29 (34.5)
    Multinodal disease                   

  Cervical lymph node involvement^e^:\   23/39 (59)\
    Present\                             16/39 (41)
    Absent                               

  Distant metastases at diagnosis^f^:\   6/42 (14.3)\
    Total\                               4/42 (9.5)\
    Lungs only\                          2/42 (4.8)\
    Lungs and bones\                     36/42 (85.7)
    No metastasis                        
  ------------------------------------------------------

Number of patients with unknown status: ^a^2; ^b^22; ^c^17; ^d^16; ^e^6; ^f^3

###### Tumor features in patients with or without lymph node (LN) metastases

                               Without LN involvement   With LN involvement   p value
  ---------------------------- ------------------------ --------------------- ---------
  Number of patients           16                       23                    \-
  PTC diagnosis                12/16 (75%)              23/23 (100%)          0.022
  Age (yrs)                    15.5 IQR (14-16)         14 IQR (13-16.5)      0.443
  Male gender                  0/16 (0%)                4/23 (17.4%)          0.130
  Tumor size (mm)              15 IQR (9-22)            26 IQR (18.8-33.5)    0.028
  Capsule infiltration         1/9 (11.1%)              6/13 (46.2%)          0.165
  Involvement of both lobes    1/12 (8.3%)              7/15 (46.7%)          0.043
  Multinodal thyroid disease   1/12 (8.3%)              8/16 (50%)            0.039
  Distant metastases           0/15 (0%)                6/23 (26.1%)          0.063
  Postoperative Tg             68.7 IQR (44.1-93.4)     13.6 IQR (8.8-40.8)   0.248
  Patients receiving I^131^    13/14 (92.9%)            22/23 (95.7%)         1.000
  Total RAI activity           99.5 IQR (55-161.8)      150 IQR (100-258.5)   0.064
  Number of applications       1 IQR (1-1.8)            2 IQR (1-2)           0.146
  Overall survival             100%                     100%                  \-
  5-year PFS                   85.9%                    84.6%                 0.620

PTC = papillary thyroid cancer; Tg = thyroglobulin; RAI = radioiodine therapy; PFS = progression free survival; IQR = interquartile range

###### Tumor features in patients with and without distant metastases

                                    Without distant metastases   With distant metastases   p value
  --------------------------------- ---------------------------- ------------------------- ---------
  Number of patients                36                           6                         \-
  PTC diagnosis                     31/35 (88.6%)                6/6 (100%)                1.000
  Age (yrs)                         15 IQR (13.8-16)             15 IQR (13.3-16.8)        0.913
  Female gender                     33/36 (91.7%)                5/6 (83.3%)               0.474
  Tumor size (mm)                   20 IQR (10-24.3)             50 IQR (44.8-51.3)        0.002
  Capsule infiltration              5/20 (25%)                   2/2 (100%)                0.091
  Involvement of both lobes         7/24 (29.2%)                 2/4 (50%)                 0.574
  Multinodal thyroid disease        8/25 (32%)                   2/4 (50%)                 0.592
  Cervical lymph node involvement   17/32 (53.1%)                6/6 (100%)                0.063
  Postoperative Tg                  43.7 IQR (15.5-80.5)         13.6 IQR (13.6-13.6)      0.480
  Patients receiving I-131          32/35 (91.4%)                6/6 (100%)                1.000
  Total RAI activity                100 IQR (55-167.5)           532.5 IQR (346.3-730)     \<0.001
  Number of applications            1 IQR (1-2)                  5.5 IQR (2.8-6.8)         \<0.001
  Overall survival                  100%                         100%                      \-
  5-year PFS                        86.8%                        83.3%                     0.631

PTC = papillary thyroid cancer; Tg = thyroglobulin; RAI = radioiodine therapy; PFS = progression free survival; IQR = interquartile range

![The number of patients diagnosed with differentiated thyroid cancer (DTC) was stable over time until the last decade, when a substantial increase in the number of newly diagnosed cases was observed. There was a significant positive trend of increase in the number of DTC patients over time. Time is shown in 5-year intervals.](acc-58-119-f1){#f1}

![Analysis of patients divided into tertiles of the study period. PFS = progression free survival](acc-58-119-f2){#f2}

Tumor characteristics
---------------------

The median tumor size was 20.5 mm (IQR 11-28), and larger tumor size positively correlated with total I-131 activity (Rho 0.46, p=0.016) and number of I-131 applications (Rho=0.046, p=0.017). The presence of cervical lymph node metastasis (LNM) was significantly associated with papillary thyroid cancer (PTC) histology (66% *vs*. 0% for PTC and follicular thyroid cancer (FTC), respectively; p=0.022), larger tumor size (26 mm *vs*. 15 mm for presence and absence of LNM; p=0.028), involvement of two thyroid lobes (88% *vs*. 42% for bilobar and unilobar tumor, respectively; p=0.043) and multifocal tumor (89% *vs*. 42% for multi- and unifocal tumor, respectively; p=0.039). A trend toward statistical significance was observed for association of LNM and presence of distant metastases (26% *vs*. 0% of patients for presence and absence of LNM, respectively; p=0.063), as well as for association of LNM and higher total I-131 activity (5500 MBq \[150 mCi\] *vs*. 3700 MBq \[100 mCi\] for presence and absence of LNM, respectively; p=0.064). The presence of distant metastases was significantly associated with larger tumor size (50 mm *vs*. 20 mm for presence and absence of distant metastases, respectively; p=0.002), higher total I-131 activity (19720 MBq \[533 mCi\] *vs.* 3700 MBq \[100 mCi\] for presence and absence of distant metastases, respectively; p\<0.001) and higher number of I-131 activity applications (6 *vs*. 1 for presence and absence of distant metastases, respectively; p\<0.001). Tumors infiltrating capsule were significantly larger in size (median 33 *vs*. 14 mm for infiltrating and non-infiltrating tumors, respectively; p=0.01). No other significant associations were observed.

Survival analyses
-----------------

The median follow-up of our cohort was 5.9 years. None of the patients died during the follow-up period. Five-year and 10-year OS rates were 100% (median OS was not reached). No secondary malignancies were detected during follow-up, however, 9 relapses were observed. All relapsing patients experienced recurrence of disease in the neck, while three patients additionally had lung metastasis. Median PFS was not reached, with 5-year PFS rate of 87% and 10-year PFS rate of 73%, as shown in [Figure 3A](#f3){ref-type="fig"}. Male gender (hazard ratio \[HR\] 4.22, p=0.046), age ≤15 years (HR 7.18, p=0.029), and tumor size \>15 mm (HR 6.29, p=0.042) were significantly associated with inferior PFS, as shown in [Figure 3B](#f3){ref-type="fig"}, [Figure 3C](#f3){ref-type="fig"}, and [Figure 3D](#f3){ref-type="fig"}, respectively. I-131 activity higher than 4366 MBq (118 mCi) (HR 8.87, p=0.001), and more than one I-131 application necessary for disease control in the setting of more advanced initial disease (HR 11.37, p=0.003) were also associated with inferior PFS. There was no statistically significant effect of histopathologic diagnosis, capsule infiltration, number of tumor focuses, presence of cervical LNM, distant metastases or Tg level on PFS.

![(A) Progression free survival (PFS) curve for all patients; 5-year PFS was 87%; (B) PFS curve by gender; male gender was significantly associated with inferior PFS (hazard ratio \[HR\] 4.22, p=0.046); (C) PFS by age; age ≤15 years was significantly associated with inferior PFS (HR 7.18, p=0.029); (D) PFS by tumor size; tumor size \>15 mm was significantly associated with inferior PFS (HR 6.29, p=0.042).](acc-58-119-f3){#f3}

Discussion
==========

Results of the present study indicated a worrying increasing trend in the number of new cases of pediatric DTC, with a substantial number of newly diagnosed cases in the last 10 years. The incidence of pediatric DTC appears to be increasing worldwide ([@r16]). However, the observed increase in the number of cases during the last decade could have been due to the true rising incidence of pediatric DTC, but could also reflect other reasons (more patients referred to the institution, earlier diagnosis and detection of clinically less significant tumors). Analyses in this study were based on age cut-off of 18 years and were not directly comparable to the results of previously published studies that used different age cut-offs with the goal of defining a population of pediatric/young adult patients with DTC (17 to 30 years of age, mixed pre-pubertal, post-pubertal and young adult population) ([@r4], [@r7], [@r8], [@r16]-[@r21]). Larger tumors had significantly higher rates of LNM and distant metastases. Involvement of two thyroid lobes and multifocal tumor were also significantly linked with higher LNM rates, but the results were not statistically significant in relation to the initial presence of distant metastases. These results are in accordance with the study conducted by Kim *et al*., which found the increasing tumor size and multifocal disease to be independent factors associated with LNM in pediatric DTC ([@r22]).

In pediatric population, the goal of radiation is most commonly to eradicate known residual disease (micro-metastases), rather than to ablate the normal thyroid remnant only ([@r10]). The increasing trend of I-131 application in patients under 25 years of age is reported, with percentages of patients receiving I-131 increasing from 4% in 1973 to 62% in 2008. This phenomenon is present despite the increasing proportion of patients with low-risk features ([@r12]). There are many data on I-131 use in thyroid cancer patients in adults ([@r23]-[@r32]). However, there are no randomized prospective clinical studies that address the issue of I-131 benefit in pediatric DTC population, dose-response relationship, or thyroid remnant ablation ([@r13]).The benefit of I-131 in pediatric DTC was confirmed in the studies by Handkiewicz-Junak *et al*. and Chow *et al*. ([@r6], [@r8]). However, even patients with low-risk disease may still be at risk of residual cervical disease and they might also have indication for adjuvant I-131 therapy ([@r10]).

The biggest concern in the application of multiple and high activities of I-131 is development of secondary malignancies. In a population-based analysis by Marti *et al*., which included patients aged \<25 years, an increased risk of second malignancy was detected after I-131 therapy and it was slightly higher in children than in adult population ([@r12]). The greatest risk of second primary malignancies occurs within 5 years of diagnosis and is higher in younger patients ([@r33]). The threshold activity for the development of secondary malignancies is difficult to determine, however, some studies proposed cumulative activities of I-131 above 7400 MBq (200 mCi) and 11100 MBq (300 mCi) ([@r13], [@r34]). The cumulative activities commonly administered to patients with distant metastases are usually much higher than the proposed thresholds. Regardless of the high cumulative activity, no secondary malignancies occurred in our cohort of patients.

As stated before, 9 relapses occurred in this cohort of patients. All patients experienced regional recurrence, and hematogenous dissemination to the lungs occurred in three patients. There were no distant metastases without lymph node involvement, with good 5-year and 10-year PFS rates of 87% and 73%, respectively. This is in line with previously reported PFS rates that are considered to be much better than in adult patients ([@r6], [@r8], [@r35]). Male gender, age 15 years or younger, and tumor size of more than 15 mm were significantly associated with inferior PFS in this cohort of patients. Although there was no significant difference in unfavorable disease features between genders or age groups, it has been previously reported that they may exist ([@r20]). It is important to stress that significant association of larger I-131 activity and higher number of I-131 applications with inferior PFS is a consequence of more aggressive disease presentation mandating a more intensive approach, and should not be interpreted as a sign of therapy insufficiency/harm. The prognosis would probably be even worse if I-131 activity was reduced or omitted in these patients.

Limitations of our study were retrograde study design, small number of patients, incomplete number of observations for all patients, and long period of data collection (50 years). However, our observations represent a valuable contribution to the pool of knowledge about this rare tumor of pediatric age.

In conclusion, the incidence of pediatric thyroid cancer appears to be increasing worldwide, although it is not yet clear whether this is true increase or it is due to better detection of the disease. Male gender, age ≤15 years, and tumor size \>15 mm were significantly associated with inferior PFS in this cohort of patients. All activities should be carried out in centers which employ a multidisciplinary team approach and have the necessary expertise in the management of pediatric thyroid cancer patients.
